TheEdgeResearch
Home / Stocks / SSMXF

Sysmex Corporation (SSMXF)

OTC Healthcare Medical - Instruments & Supplies
$10.40 ▲ +0.00%
Market Cap
$6.46B
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Beta
0.69
52-Wk Range
7.97-13.92
CEO
Hisashi Ietsugu
Country
JP
Currency
USD

Sysmex Corporation operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in Kobe, HY, JP. The stock last traded at $10.40, up 0.00% on the session, giving a market capitalisation of $6.46B. On trailing twelve-month figures it carries a trailing P/E of 30.36, a net margin of 7.5%. Its beta of 0.69 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
30.36
Price / Sales
2.22
Price / Book
2.44
EV / EBITDA
10.80
Gross margin
51.0%
Operating margin
13.1%
Net margin
7.5%
Return on equity
Debt / equity
0.25
Current ratio
3.40
Dividend yield
2.0%
Payout ratio
59.7%
Company profile
Exchange
Other OTC
Employees
10,861
IPO date
2009-04-21
Headquarters
Kobe, HY, JP
About Sysmex Corporation

Headquartered in Kobe, Japan, Sysmex Corporation is a global leader in the creation, production, and distribution of sophisticated diagnostic instruments, chemical reagents, and related software. Their extensive product portfolio addresses a wide array of laboratory needs. Within hematology, Sysmex provides advanced three-part and five-part white blood cell differentiation instruments, alongside efficient transport systems designed for high-throughput laboratory environments. Their offerings further encompass automated analyzers for both urine particles and blood coagulation. The company also specializes in automated immunochemistry systems, capable of performing intricate assays on minute sample volumes, complemented by reagents for detecting infectious diseases and tumor markers. Additionally, Sysmex manufactures essential flow cytometers utilized in diagnosing conditions such as leukemia, malignant lymphoma, and HIV/AIDS. Beyond these core diagnostic tools, Sysmex offers specialized systems for detecting cancer lymph node metastasis and provides comprehensive laboratory assay services. The company's operations extend into developing and commercializing software for diagnostic information systems, and delivering a range of services including facility management, administrative support, employee welfare, and genetic analysis. They are deeply involved in the conception, operation, and maintenance of IT solutions, platforms, and applications tailored for digital medicine. Sysmex also actively participates in the entire lifecycle of medical robots, from marketing and development to design, manufacturing, sales, and post-sales support. Furthermore, the company manages the distribution and after-sales support for medical devices and reagents used across biotechnology, medical technology, and molecular cell analysis. Sysmex is committed to research, development, manufacturing, and commercialization of regenerative medicine products and biodevices, while also developing, maintaining, and selling general computer software and offering blood DNA testing services. Sysmex serves a diverse international client base, including national and public hospitals, private healthcare facilities, universities, research institutions, and various other medical organizations. Their global reach is substantial, with product exports to approximately 190 countries. Founded in 1968, the company initially operated as TOA Medical Electronics Co., Ltd., adopting the name Sysmex Corporation in October 1998.

Comparable companies

Sysmex Corporation is most often compared with the following Healthcare names:

CNVVFCNVVYESAIYESALFGIFOFSHPMFSHTDYWILLFWILYYYPHDF
More research on SSMXF
SSMXF technical analysis SSMXF TheEdge Score Compare against peers
Open full interactive analysis & DCF →